{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:10:55Z","timestamp":1790723455168,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77041-x","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:35:31Z","timestamp":1788147331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015)"],"prefix":"10.1038","volume":"17","author":[{"given":"Dechuang","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiujun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenduo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3911-748X","authenticated-orcid":false,"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3878-1258","authenticated-orcid":false,"given":"Zhenzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"77041_CR1","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl. Cancer Inst. 106, dju055 (2014).","journal-title":"J. Natl. Cancer Inst."},{"key":"77041_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert, C. et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 22, 1151\u20131161 (2021).","journal-title":"Lancet Oncol."},{"key":"77041_CR3","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J. Clin. Oncol. 41, 3867\u20133872 (2023).","journal-title":"J. Clin. Oncol."},{"key":"77041_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.19.01455","volume":"38","author":"L Fehrenbacher","year":"2020","unstructured":"Fehrenbacher, L. et al. NSABP B-47\/NRG oncology phase iii randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J. Clin. Oncol. 38, 444\u2013453 (2020).","journal-title":"J. Clin. Oncol."},{"key":"77041_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring, L. M. et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2, 1477\u20131486 (2016).","journal-title":"JAMA Oncol."},{"key":"77041_CR6","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1200\/JCO.2007.10.9710","volume":"25","author":"HB Muss","year":"2007","unstructured":"Muss, H. B. et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J. Clin. Oncol. 25, 3699\u20133704 (2007).","journal-title":"J. Clin. Oncol."},{"key":"77041_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1200\/JCO.2003.03.114","volume":"21","author":"RE Smith","year":"2003","unstructured":"Smith, R. E., Bryant, J., DeCillis, A. & Anderson, S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J. Clin. Oncol. 21, 1195\u20131204 (2003).","journal-title":"J. Clin. Oncol."},{"key":"77041_CR8","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jamaoncol.2021.2132","volume":"7","author":"T Sella","year":"2021","unstructured":"Sella, T. et al. Neoadjuvant endocrine therapy in clinical practice: a review. JAMA Oncol. 7, 1700\u20131708 (2021).","journal-title":"JAMA Oncol."},{"key":"77041_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med"},{"key":"77041_CR10","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.esmoop.2023.101374","volume":"8","author":"HS Rugo","year":"2023","unstructured":"Rugo, H. S. et al. 185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low unresectable and\/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial. ESMO Open 8, 101374 (2023).","journal-title":"ESMO Open"},{"key":"77041_CR11","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.23.02044","volume":"42","author":"H Yao","year":"2024","unstructured":"Yao, H. et al. Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2-directed antibody-drug conjugate, in human epidermal growth factor receptor 2-expressing or mutated advanced solid tumors: a global phase I trial. J. Clin. Oncol. 42, 3453\u20133465 (2024).","journal-title":"J. Clin. Oncol."},{"key":"77041_CR12","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/annonc\/mds132","volume":"23","author":"E Alba","year":"2012","unstructured":"Alba, E. et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM\/2006-03, a multicenter, randomized, phase-II study. Ann. Oncol. 23, 3069\u20133074 (2012).","journal-title":"Ann. Oncol."},{"key":"77041_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10549-014-3183-4","volume":"148","author":"C Palmieri","year":"2014","unstructured":"Palmieri, C. et al. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Res Treat. 148, 581\u2013590 (2014).","journal-title":"Breast Cancer Res Treat."},{"key":"77041_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/cncr.22789","volume":"110","author":"VF Semiglazov","year":"2007","unstructured":"Semiglazov, V. F. et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110, 244\u2013254 (2007).","journal-title":"Cancer"},{"key":"77041_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso, F. et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)\/HER2(-) breast cancer: a randomized phase 3 trial. Nat. Med. 31, 442\u2013448 (2025).","journal-title":"Nat. Med."},{"key":"77041_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi, S. et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat. Med 31, 433\u2013441 (2025).","journal-title":"Nat. Med"},{"key":"77041_CR17","doi-asserted-by":"publisher","first-page":"e1473","DOI":"10.1634\/theoncologist.2020-0001","volume":"25","author":"B Yang","year":"2020","unstructured":"Yang, B. et al. Current status and factors influencing surgical options for breast cancer in china: a nationwide cross-sectional survey of 110 hospitals. oncologist 25, e1473\u2013e1480 (2020).","journal-title":"oncologist"},{"key":"77041_CR18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring, L. M. et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395, 817\u2013827 (2020).","journal-title":"Lancet"},{"key":"77041_CR19","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma, C. X. et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin. Cancer Res. 23, 4055\u20134065 (2017).","journal-title":"Clin. Cancer Res."},{"key":"77041_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","volume":"26","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz, S. A. et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR(+)\/HER2(-) breast cancer. Clin. Cancer Res. 26, 566\u2013580 (2020).","journal-title":"Clin. Cancer Res."},{"key":"77041_CR21","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1093\/annonc\/mdy448","volume":"29","author":"P Cottu","year":"2018","unstructured":"Cottu, P. et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann. Oncol. 29, 2334\u20132340 (2018).","journal-title":"Ann. Oncol."},{"key":"77041_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/JCO.18.01624","volume":"37","author":"S Johnston","year":"2019","unstructured":"Johnston, S. et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J. Clin. Oncol. 37, 178\u2013189 (2019).","journal-title":"J. Clin. Oncol."},{"key":"77041_CR23","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S1470-2045(19)30334-1","volume":"20","author":"C Saura","year":"2019","unstructured":"Saura, C. et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 20, 1226\u20131238 (2019).","journal-title":"Lancet Oncol."},{"key":"77041_CR24","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga, J. et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27, 2630\u20132637 (2009).","journal-title":"J. Clin. Oncol."},{"key":"77041_CR25","first-page":"5","volume":"83","author":"A Bardia","year":"2023","unstructured":"Bardia, A. et al. Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer 83, 5 (2023).","journal-title":"early stage breast cancer"},{"key":"77041_CR26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2016.69.4406","volume":"35","author":"J Matthew","year":"2017","unstructured":"Matthew, J. et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J. Clin. Oncol. 35, 1061 (2017).","journal-title":"J. Clin. Oncol."},{"key":"77041_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"M Shanu","year":"2022","unstructured":"Shanu, M. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"77041_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"L-C Tsao","year":"2025","unstructured":"Tsao, L.-C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat. Commun. 16, 3167 (2025).","journal-title":"Nat. Commun."},{"key":"77041_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.trecan.2019.12.010","volume":"6","author":"G-A Sara","year":"2020","unstructured":"Sara, G.-A., Alberto, O. & Atanasio, P. J. T. C. Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond. Trends Cancer 6, 130\u2013146 (2020).","journal-title":"Trends Cancer"},{"key":"77041_CR30","first-page":"22","volume":"7","author":"S Khalil","year":"2024","unstructured":"Khalil, S. et al. Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer. Cancer Drug Resist 7, 22 (2024).","journal-title":"Cancer Drug Resist"},{"key":"77041_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","volume":"26","author":"L Ziming","year":"2025","unstructured":"Ziming, L. et al. Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. Lancet Oncol. 26, 437\u2013446 (2025).","journal-title":"Lancet Oncol."},{"key":"77041_CR32","doi-asserted-by":"publisher","first-page":"e0326691","DOI":"10.1371\/journal.pone.0326691","volume":"20","author":"Z Ting","year":"2025","unstructured":"Ting, Z. et al. SHR-A1811, a novel anti-HER2 antibody-drug conjugate with an optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. One 20, e0326691 (2025).","journal-title":"One"},{"key":"77041_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"77041_CR34","doi-asserted-by":"crossref","unstructured":"Compton C. C., et al. AJCC cancer staging atlas. 2nd edn. (New York, NY: Springer-Verlag, 2012).","DOI":"10.1007\/978-1-4614-2080-4"},{"key":"77041_CR35","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v.5.0 (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (2025)."},{"key":"77041_CR36","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"M Laura","year":"2016","unstructured":"Laura, M. et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2, 1477\u20131486 (2016).","journal-title":"JAMA Oncol."},{"key":"77041_CR37","doi-asserted-by":"publisher","unstructured":"Dechuang J., et al. Patient-level clinical dataset from HELEN-015 phase 2 neoadjuvant SHR-A1811 trial in HR+\/HER2-low breast cancer [dataset]. Figshare https:\/\/doi.org\/10.6084\/m9.figshare. (2026).","DOI":"10.6084\/m9.figshare"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77041-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77041-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77041-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:43:29Z","timestamp":1790721809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77041-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77041"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77041-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10339"}}